News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
RA CAPITAL MANAGEMENT, L.P.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/24/2023 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 7.8% stake in MINERALYS THERAPEUTICS, INC. |
| 11/28/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 05/20/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 09/27/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 14.3% stake in DICE Therapeutics, Inc. |
| 09/27/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 17% stake in Tyra Biosciences, Inc. |
| 08/19/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 50% stake in Eliem Therapeutics, Inc. |
| 08/12/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 14.7% stake in Icosavax, Inc. |
| 08/06/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 7.2% stake in Cytek BioSciences, Inc. |
| 07/16/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 25.3% stake in Acumen Pharmaceuticals, Inc. |
| 07/12/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 33.9% stake in Aerovate Therapeutics, Inc. |
| 06/30/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 7.8% stake in Therapeutics Acquisition Corp. |
| 06/16/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 20.8% stake in Janux Therapetuics, Inc. |
| 05/06/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 14.4% stake in Werewolf Therapeutics, Inc. |
| 04/16/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 12.3% stake in Achilles Therapeutics plc |
| 03/29/2021 |
SC 13D
| RA CAPITAL MANAGEMENT, L.P. reports a 11.5% stake in CONNECT BIOPHARMA HOLDINGS LIMITED |
| 02/19/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 08/05/2020 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 13.2% stake in iTeos Therapeutics, Inc. |
| 07/24/2020 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 17.2% stake in Nkarta, Inc. |
| 06/25/2020 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/05/2020 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 7.2% stake in Black Diamond Therapeutics, Inc. |
| 11/13/2019 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 26.2% stake in 89bio, Inc. |
| 09/17/2019 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 28.2% stake in Satsuma Pharmaceuticals, Inc. |
| 07/02/2018 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 5.9% stake in Eidos Therapeutics, Inc. |
| 04/02/2018 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 7.1% stake in BIOCRYST PHARMACEUTICALS, INC. |
| 02/09/2018 |
SC 13D
| RA CAPITAL MANAGEMENT, LLC reports a 7.9% stake in Solid Biosciences Inc. |
| 02/14/2017 |
SC 13D
| KalVista Pharmaceuticals, Inc. reports a 6% stake in Kalvista Pharmaceuticals, Inc. |
| 11/09/2016 |
SC 13D
| Ra Pharmaceuticals, Inc. reports a 6.3% stake in Ra Pharmaceuticals, Inc. |
| 09/13/2010 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership |
|
|